Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis.
BACKGROUND
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that specifically affects motor neurons and leads to a progressive and ultimately fatal loss of function, resulting in death typically within 3 to 5 years of diagnosis. The disease starts with a focal centre of weakness, such as one limb, and appears to spread to other parts of the body. Mutations in superoxide dismutase 1 (SOD1) are known to cause disease and it is generally accepted they lead to pathology not by loss of enzymatic activity but by gain of some unknown toxic function(s). Although different mutations lead to varying tendencies of SOD1 to aggregate, we suggest abnormal proteins share a common misfolding pathway that leads to the formation of amyloid fibrils.


RESULTS
Here we demonstrate that misfolding of superoxide dismutase 1 leads to the formation of amyloid fibrils associated with seeding activity, which can accelerate the formation of new fibrils in an autocatalytic cascade. The time limiting event is nucleation to form a stable protein "seed" before a rapid linear polymerisation results in amyloid fibrils analogous to other protein misfolding disorders. This phenomenon was not confined to fibrils of recombinant protein as here we show, for the first time, that spinal cord homogenates obtained from a transgenic mouse model that overexpresses mutant human superoxide dismutase 1 (the TgSOD1(G93A) mouse) also contain amyloid seeds that accelerate the formation of new fibrils in both wildtype and mutant SOD1 protein in vitro.


CONCLUSIONS
These findings provide new insights into ALS disease mechanism and in particular a mechanism that could account for the spread of pathology throughout the nervous system. This model of disease spread, which has analogies to other protein misfolding disorders such as prion disease, also suggests it may be possible to design assays for therapeutics that can inhibit fibril propagation and hence, possibly, disease progression.
Chia
Ruth
R
Department of Neurodegenerative Disease, University College London Institute of Neurology, London, United Kingdom.
Tattum
M Howard
MH
Jones
Samantha
S
Collinge
John
J
Fisher
Elizabeth M C
EM
Jackson
Graham S
GS
D000682:Amyloid / Q000378:metabolism* / Q000648:ultrastructure; D000690:Amyotrophic Lateral Sclerosis / Q000201:enzymology* / Q000473:pathology*; D000818:Animals; D052160:Benzothiazoles; D016923:Cell Death; D006801:Humans; D007700:Kinetics; D051379:Mice; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D055550:Protein Stability; D013116:Spinal Cord / Q000201:enzymology* / Q000473:pathology* / Q000648:ultrastructure; D013347:Subcellular Fractions / Q000201:enzymology; D013482:Superoxide Dismutase / Q000378:metabolism* / Q000648:ultrastructure; D000072105:Superoxide Dismutase-1; D013844:Thiazoles / Q000378:metabolism; D013997:Time Factors
D000682:Amyloid; D052160:Benzothiazoles; C000606290:SOD1 protein, human; D013844:Thiazoles; C009462:thioflavin T; C000606291:Sod1 protein, mouse; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1